|  | Cancer | Cancer Treatment

Multiple Myeloma: Treatment Landscape and Care Access

Multiple myeloma (MM) is a plasma cell malignancy. Treatment is stratified by transplant eligibility, risk stratification (R-ISS), and patient factors.

Standard Treatment Phases

  1. Induction: Triplet regimens preferred.
    • Transplant-eligible: VRd (bortezomib/lenalidomide/dex), D-VRd (daratumumab + VRd), KRd (carfilzomib-based).
    • Transplant-ineligible: DRd (daratumumab/len/dex), VRd-lite, Rd (len/dex).
  2. Consolidation: High-dose melphalan (HDM) + autologous stem cell transplant (ASCT) for eligible patients. Tandem transplant in select trials.
  3. Maintenance: Lenalidomide (standard); bortezomib/len for high-risk; daratumumab-based in trials. Continue until progression/toxicity.
  4. Relapse/Refractory: Sequential lines: anti-CD38 (daratumumab, isatuximab), proteasome inhibitors (carfilzomib, ixazomib), IMiDs (pomalidomide), BCL-2 inhibitor (venetoclax for t(11;14)), bispecifics (teclistamab, talquetamab), CAR-T (ide-cel, ciltacabtagene). Clinical trials prioritized.

Supportive Care

  • Bone health: Zoledronic acid/denosumab.
  • Infection prophylaxis: IVIG if hypogammaglobulinemia; antivirals, PJP prophylaxis.
  • Renal protection, anemia management, VTE prophylaxis.

Finding Expert Care

Seek NCI-designated Comprehensive Cancer Centers or academic myeloma programs (IMWG-affiliated). Multidisciplinary team: hematologist, transplant specialist, nurse navigator, pharmacist, social worker. NCCN Guidelines and SparkCures/ClinicalTrials.gov for trial matching.

Cancer Treatment - Related Articles